- Home
- NB vs CTMX Comparison
NB vs CTMX Comparison
Compare NB & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NB | CTMX |
|---|---|---|
| Founded | 1987 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 737.6M | 596.2M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | NB | CTMX |
|---|---|---|
| Price | $5.34 | $5.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $6.75 | ★ $8.86 |
| AVG Volume (30 Days) | ★ 5.9M | 3.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $138,103,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $22.58 |
| Revenue Growth | N/A | ★ 36.45 |
| 52 Week Low | $1.60 | $0.40 |
| 52 Week High | $12.58 | $6.35 |
Technical Indicators
Market Signals| Indicator | NB | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 42.00 | 50.90 |
| Support Level | $5.31 | $5.03 |
| Resistance Level | $6.35 | $5.61 |
| Average True Range (ATR) | 0.54 | 0.44 |
| MACD | -0.11 | -0.09 |
| Stochastic Oscillator | 3.95 | 25.00 |
Price Performance
Historical ComparisonAbout NB NioCorp Developments Ltd.
NioCorp Developments Ltd is engaged in exploration and development of mineral deposits in North America, specifically, the Elk Creek Niobium/Scandium/Titanium property.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.